This pilot study added apabetalone to people's PAH therapy twice daily for 16 weeks to see if a future clinical trial evaluating bromodomain inhibition in pulmonary arterial hypertension might be feasible. They also aimed to provide preliminary evidence that apabetalone may be safe and effective in PAH.
top of page
Recent Posts
The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...
Great news for the Pulmonary Hypertension (PH) community! Through the Canadian Drug Agency's (CDA) funding initiative for rare diseases,...
As most PH clinics are in large cities, PH patients living in rural or remote areas and who must travel long distances to their clinic...
bottom of page
Comments